Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eucomed responds over EU's hTEPS (human tissue engineered products) U-turn:

This article was originally published in Clinica

Executive Summary

Eucomed, the European medical device industry association, can accept that the overall regulatory framework for human tissue engineered products (hTEPs) is linked to the EU pharmaceutical legislation for the sake of speedy regulation. However, steps taken to ensure that any modifications to the Regulation on Medicinal Products for Human Use will appropriately take into account that hTEPs are NOT medicinal products. This is the official response of Eucomed, released as Clinica went to press, to the European Commission's proposal for a community Regulatory Framework on Advanced Therapies, the deadline for which was originally June 20, but was ultimately extended by one week. Clinica will cover more Eucomed detailed comments in issue No 1164.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel